Previous studies have shown that CYP7A1 and its associated cholesterol processes were adversely regulated in NAFLD (Wruck and Adjaye, 2017), and glucose stimulates CYP7A1 transcription in human hepatocytes (Chiang and Ferrell, 2020). This evidence concerns the gene CYP7A1 and metabolic dysfunction-associated steatotic liver disease.